New bi-specific monoclonal antibody to be tested in myeloma

Glenmark Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its proprietary drug GBR 1342 to be investigated as a treatment for myeloma patients. GBR 1342 is a humanised bi-specific monoclonal antibody designed to activate the immune system by redirecting T cells to myeloma…

Details